GeneDx Hldgs Q3 2024 GAAP EPS $(0.31) Beats $(0.50) Estimate, Sales $76.87M Beat $64.99M Estimate
Portfolio Pulse from Benzinga Newsdesk
GeneDx Holdings (NASDAQ:WGS) reported better-than-expected Q3 2024 results with a GAAP EPS of $(0.31), beating the estimate of $(0.50), and sales of $76.87M, surpassing the $64.99M estimate. Sales increased by 44.22% compared to the same period last year.
October 29, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GeneDx Holdings reported a Q3 2024 GAAP EPS of $(0.31), beating the $(0.50) estimate, and sales of $76.87M, exceeding the $64.99M estimate. Sales grew by 44.22% YoY.
GeneDx Holdings' better-than-expected earnings and sales figures are likely to positively impact its stock price in the short term. The significant beat on both EPS and sales estimates, along with a strong year-over-year sales growth, indicates strong operational performance, which is typically viewed favorably by investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100